Researchers at the Case Western Reserve University School of Medicine received a $ 2.5 million grant from Gilead Sciences, a biopharmaceutical company in California, to see if the two treatment programs that have been used alone so far can be more effective. Michael M. Lederman, a leading investigator professor of medicine, and colleagues used recombinant horse proteins and combined interleukin-2 (a protein produced by the body that stimulates human killer cells) with a laboratory-designed monoclonal antibody targeting HIV.

"The use of Il-2 alone and certain monoclonal antibodies can reduce but not necessarily eliminate the presence of HIV," Dr. Lederman said. "Our research will proceed to the next step and use them together. We want to see if they are separate management to produce more synergies."

Neutralizing HIV IL-2 and monoclonal antibodies have been safely administered to HIV-infected but not yet used in combination. The researchers will monitor the safety and tolerability of the study participants. A key objective of this study is to determine whether new combination therapy can reduce the latent HIV database, which includes HIV-infected cells that are not actively producing HIV. Even in the case of HIV infection, there is no detectable level of HIV in the blood, and it is difficult to measure the HIV database. Although not active, but the reservoir proved no cure, because they can be re-activated for many reasons.

IL-2 has been approved by the Food and Drug Administration for the treatment of certain cancers. It activates killer cells and activates HIV at latency. Neutralizing HIV monoclonal antibodies are cloned protein antibodies that are immune cells that bind to the surface of HIV and prevent infection. They can also help to kill cells that have been infected with HIV-infected cells from latency.

In a 64-week study, patients in a treatment group will receive IL-2, while patients in the second treatment group will receive IL-2 plus neutralized HIV monoclonal antibodies. It is hoped that in both groups, the size of the HIV library will be reduced and the antibody will make IL-2 treatment more effective. The study will include 16 patients starting from the second half of 2017.

Previous retrospective studies have shown that IL-2 therapy can reduce the size of latent HIV pools. "We believe that it is important to try to confirm these findings in prospective trials and to see if adding monoclonal antibodies enhances IL-2 activity," Dr. Lederman said. He and his research colleagues are discussing with the National Institutes of Health's Vaccine Research Center to determine whether monoclonal antibodies are used in several centers for the prevention or treatment of HIV infection. Flarebio offers good-quality recombinant proteins and antibodies including GFAP Monoclonal Antibody for your research.